ATE397075T1 - Chimärisches , adenovirales faserprotein und verfahren zu dessen verwendung - Google Patents

Chimärisches , adenovirales faserprotein und verfahren zu dessen verwendung

Info

Publication number
ATE397075T1
ATE397075T1 AT96906417T AT96906417T ATE397075T1 AT E397075 T1 ATE397075 T1 AT E397075T1 AT 96906417 T AT96906417 T AT 96906417T AT 96906417 T AT96906417 T AT 96906417T AT E397075 T1 ATE397075 T1 AT E397075T1
Authority
AT
Austria
Prior art keywords
adenoviral
chimeric adenoviral
chimeric
fiber protein
amino acid
Prior art date
Application number
AT96906417T
Other languages
English (en)
Inventor
Thomas Wickham
Erik Falck-Pedersen
Petrus Roelvink
Joseph Bruder
Jason Gall
Imre Kovesdi
Original Assignee
Genvec Inc
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc, Cornell Res Foundation Inc filed Critical Genvec Inc
Application granted granted Critical
Publication of ATE397075T1 publication Critical patent/ATE397075T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345Special targeting system for viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405Vectors comprising RGD peptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018Adenoviridae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT96906417T 1995-02-21 1996-02-13 Chimärisches , adenovirales faserprotein und verfahren zu dessen verwendung ATE397075T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/395,381 US5770442A (en) 1995-02-21 1995-02-21 Chimeric adenoviral fiber protein and methods of using same

Publications (1)

Publication Number Publication Date
ATE397075T1 true ATE397075T1 (de) 2008-06-15

Family

ID=23562798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96906417T ATE397075T1 (de) 1995-02-21 1996-02-13 Chimärisches , adenovirales faserprotein und verfahren zu dessen verwendung

Country Status (8)

Country Link
US (3) US5770442A (de)
EP (1) EP0811069B1 (de)
JP (1) JPH11500315A (de)
AT (1) ATE397075T1 (de)
AU (1) AU698254B2 (de)
CA (1) CA2213343C (de)
DE (1) DE69637545D1 (de)
WO (1) WO1996026281A1 (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ATE278794T1 (de) * 1995-06-15 2004-10-15 Crucell Holland Bv Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
AU716466B2 (en) * 1995-09-27 2000-02-24 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
EE9800160A (et) * 1995-11-28 1998-12-15 Genvec, Inc. Vektorid ja meetodid geenide ülekandmiseks rakkudesse
AU742018B2 (en) * 1996-08-21 2001-12-13 Genvec, Inc. Alternatively targeted adenovirus
US6420629B1 (en) * 1996-09-09 2002-07-16 B.C. Research Inc. Process of increasing plant growth and yield and modifying cellulose production in plants
NZ508399A (en) * 1996-09-25 2003-06-30 Novartis Ag Packaging cell lines for use in facilitating the development of high capacity adenoviral vectors
US7232899B2 (en) * 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
WO1998017322A1 (en) * 1996-10-24 1998-04-30 Genzyme Corporation And President And Fellows Of Harvard College Enhanced delivery of adenoviral vectors to lung tissue
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
WO1998041618A1 (en) * 1997-03-14 1998-09-24 Uab Research Foundation Method for the purification of virus
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
FR2761689B1 (fr) * 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
FR2761688A1 (fr) * 1997-04-02 1998-10-09 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
EP1015005A4 (de) * 1997-05-08 2002-10-16 Genetic Therapy Inc Gentransfer mit hilfe von adenovirus enthaltend modifizierte faserproteine
EP0988390A1 (de) * 1997-05-28 2000-03-29 Genvec, Inc. Adenovirus mit veränderter zielzellenspezifität
CA2294649C (en) 1997-06-23 2007-09-25 University Of Saskatchewan Bovine adenovirus type 3 genome
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
CA2327545A1 (en) * 1998-02-06 1999-08-12 Uab Research Foundation Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
US20050095231A1 (en) * 1998-02-17 2005-05-05 Curiel David T. Modified adenovirus containing a fiber replacement protein
US6815200B1 (en) 1998-02-17 2004-11-09 The Uab Research Foundation Modified adenovirus containing a fiber replacement protein
EP1070118B1 (de) * 1998-02-17 2006-10-11 The Uab Research Foundation Modifizierte adenoviren welche ein faserersatzprotein enthalten
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU4070499A (en) * 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
AU2003268608B2 (en) * 1998-07-08 2007-01-04 Crucell Holland B.V. Chimaeric adenoviruses
AU773202B2 (en) * 1998-08-27 2004-05-20 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
AU776067B2 (en) * 1999-03-04 2004-08-26 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US6869936B1 (en) * 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
WO2000067576A1 (en) * 1999-05-12 2000-11-16 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
CA2378324A1 (en) * 1999-07-06 2001-01-11 Leif Lindholm Recombinant adenovirus
CA2348158A1 (fr) * 1999-08-27 2001-03-08 Transgene S.A. Fibre adenovirale modifiee et utilisations
ES2183752T3 (es) * 1999-09-17 2005-07-16 Tgt Laboratories, S.A. De C.V. Vectores adenovirales recombinantes y su utilizacion en el tratamiento de la cirrosis de higado.
EP1276888A2 (de) * 2000-04-26 2003-01-22 Crucell Holland B.V. Adenovirale vektoren ohne knob-domäne im fiber protein, und verwendungen davon
EP1157999A1 (de) * 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
JP2003534806A (ja) * 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
US6524572B1 (en) * 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US20040033605A1 (en) * 2000-09-20 2004-02-19 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells
US7235233B2 (en) * 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
MXPA00011713A (es) * 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
JP4399255B2 (ja) * 2001-06-22 2010-01-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 細菌の形質転換体を迅速に選別する方法および新規なサルアデノウイルス蛋白質
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US20060275262A1 (en) * 2001-07-26 2006-12-07 Mathis James M Conditionally replicating viruses and methods for cancer virotherapy
US9175309B2 (en) * 2001-09-29 2015-11-03 Industry-University Cooperation Foundation Hanyang University Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
US7175983B2 (en) 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
HU230488B1 (hu) 2001-11-21 2016-08-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
AU2006204656B2 (en) * 2001-11-21 2008-01-24 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CA2474763A1 (en) * 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
KR101006594B1 (ko) 2002-04-25 2011-01-07 크루셀 홀란드 비.브이. 안정한 아데노바이러스 벡터 및 그 증식 방법
ATE447037T1 (de) * 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
AU2003223775A1 (en) * 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
WO2004007537A2 (en) * 2002-07-10 2004-01-22 Transgene S.A. Modified adenoviral fiber with ablated to cellular receptors
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (de) 2002-10-23 2005-07-20 Crucell Holland B.V. Einstellung für rekombinante adenovirus-basierte impfstoffe
CA2507915C (en) 2002-12-17 2013-07-02 Crucell Holland B.V. Recombinant viral-based malaria vaccines
ES2371913T3 (es) 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
AU2004238979B2 (en) 2003-05-14 2008-12-18 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Broadening adenovirus tropism
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7291498B2 (en) * 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
EP1636370B1 (de) * 2003-06-20 2014-04-16 The Trustees of The University of Pennsylvania Methoden, chimärische adenoviren zu erzeugen und verwendung solcher adenoviren
EP1649028B1 (de) * 2003-07-25 2012-08-22 Genvec, Inc. Adenoviralevektoren-basierte impfstoffe
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
EP1687032B1 (de) * 2003-11-14 2010-02-24 Genvec, Inc. Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
EP1718738A2 (de) 2004-02-23 2006-11-08 Crucell Holland B.V. Verfahren zur reinigung von viren
CA2563396A1 (en) 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method of using adenoviral vectors to induce an immune response
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
EP1784493A2 (de) * 2004-09-01 2007-05-16 The Government of the United States of America as Represented by The Department of Health and Human Services Adenovirale vektoren mit der fähigkeit zum umwandeln von apcs, mögliche verwendung bei immunantworterzeugung
JP2008531581A (ja) * 2005-02-23 2008-08-14 ユーエービー リサーチ ファウンデーション アルキル−グリコシドで増強されたワクチン接種
US20060205080A1 (en) * 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
US20070010016A1 (en) * 2005-03-11 2007-01-11 Mccelland Alan Gene transfer with adenoviruses having modified fiber proteins
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US8765146B2 (en) * 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
CA2646671A1 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US20080248060A1 (en) * 2007-01-09 2008-10-09 Genvec, Inc. Adenoviral vector-based malaria vaccines
US8629334B2 (en) * 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees
DK2350268T3 (en) 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
CN102791852B (zh) 2009-10-15 2014-05-07 克鲁塞尔荷兰公司 纯化腺病毒颗粒的方法
EA028875B1 (ru) 2009-10-15 2018-01-31 Янссен Вэксинс Энд Превеншн Б.В. Способ очистки аденовирусных частиц из клеточной суспензии
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
MX2012005181A (es) 2009-11-09 2012-08-01 Genvec Inc Metodos para la propagacion de vectores adenovirales de monos.
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
US9512429B2 (en) 2010-12-06 2016-12-06 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
US8920813B2 (en) 2010-12-20 2014-12-30 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
WO2013181128A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Modified serotype 28 adenoviral vectors
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2014165349A1 (en) 2013-04-04 2014-10-09 Trustees Of Dartmouth College Compositions and methods for in vivo excision of hiv-1 proviral dna
ES2711115T3 (es) 2013-09-19 2019-04-30 Janssen Vaccines & Prevention Bv Formulaciones de adenovirus mejoradas
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
BR112018006488B1 (pt) 2015-10-06 2024-03-12 Janssen Vaccines & Prevention B.V. Métodos para prevenir a degradação induzida por plástico de biológicos
WO2017070113A1 (en) 2015-10-19 2017-04-27 The United States of America, as represented by the Secretary, Department of Health and Human Sevices Pharmaceutical composition comprising nanog shrna, and method of using nanog shrna to treat cancer
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
WO2018064523A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3927833A4 (de) 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. Onkolytischer adenoviraler vektor und verfahren zur verwendung
EP4338727A1 (de) 2022-09-14 2024-03-20 Roquette Freres Adenovirus-formulierungen

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4487829A (en) * 1982-03-23 1984-12-11 Massachusetts Institute Of Technology Production and use of monoclonal antibodies against adenoviruses
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
FR2602790B1 (fr) * 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
EP0273085A1 (de) 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5674722A (en) * 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5204445A (en) * 1988-10-03 1993-04-20 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
WO1990012087A1 (en) 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
ES2096590T3 (es) * 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
JPH05504677A (ja) * 1989-10-20 1993-07-22 トラスティーズ オブ ダートマス カレッジ IgAレセプターに特異的なモノクロナール抗体
EP0595798B1 (de) * 1989-10-20 1999-03-03 Medarex, Inc. Bispezifische heteroantikörper mit zweifachen effektorfunktionen
AU7906691A (en) * 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
GB9101550D0 (en) * 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
JP3534749B2 (ja) * 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) * 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH08504091A (ja) 1992-09-22 1996-05-07 メディカル・リサーチ・カウンシル 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス
NZ256018A (en) * 1992-09-25 1997-07-27 Rhone Poulenc Rorer Sa Recombinant adenoviral vectors and their use in directing expression and transcription of selected nucleotide sequences in cells of the central nervous system
DE4232846A1 (de) * 1992-09-30 1994-03-31 Audi Ag Querträger für das Armaturenbrett eines Kraftfahrzeuges
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
ATE212665T1 (de) * 1992-11-18 2002-02-15 Arch Dev Corp Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
WO1994017832A1 (en) * 1993-02-09 1994-08-18 The Scripps Research Institute Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
JPH08509869A (ja) * 1993-05-10 1996-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 膵臓および胆管の上皮細胞への遺伝子導入
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1995006745A1 (de) * 1993-09-03 1995-03-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vektor für leber-gentherapie
US5552311A (en) * 1993-09-14 1996-09-03 University Of Alabama At Birmingham Research Foundation Purine nucleoside phosphorylase gene therapy for human malignancy
US5534423A (en) * 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
FR2712812B1 (fr) * 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IT1271461B (it) * 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
US5491565A (en) * 1993-12-03 1996-02-13 Telefonaktiebolaget Lm Ericsson System and method for varying the transmission rate of facsimile data in a telecommunication system
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6312699B1 (en) * 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JPH09509329A (ja) * 1994-05-13 1997-09-22 チロン ビアジーン,インコーポレイティド 遺伝子搬送媒体を標的とする組成物及び方法
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
FR2721943B1 (fr) * 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour une superoxyde dismutase
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
CA2199609A1 (en) * 1994-09-09 1996-03-14 Errol B. Desouza Interleukin-1 type 3 receptors
FR2724846B1 (fr) * 1994-09-27 1996-12-20 Rhone Poulenc Rorer Sa Methode de traitement des cancers par regulation de l'activite des proteines ras
DE69534166T2 (de) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
WO1996014837A1 (en) * 1994-11-09 1996-05-23 Genetic Therapy, Inc. Gene therapy for hypercholesterolemia
WO1996017073A1 (fr) * 1994-11-29 1996-06-06 Takara Shuzo Co., Ltd. Procede pour la production de cellules transformees
FR2727867B1 (fr) * 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
EE9800160A (et) * 1995-11-28 1998-12-15 Genvec, Inc. Vektorid ja meetodid geenide ülekandmiseks rakkudesse
WO1997024453A1 (en) 1995-12-28 1997-07-10 Chiron Corporation Receptor specific chimeric viral surface polypeptides for viral and particle incorporation and internalization in target cells
AU2678097A (en) 1996-04-16 1997-11-07 Immusol Incorporated Targeted viral vectors
WO1998011221A2 (en) 1996-09-13 1998-03-19 Dana-Farber Cancer Institute Car, a novel coxsackievirus and adenovirus receptor
NZ508399A (en) 1996-09-25 2003-06-30 Novartis Ag Packaging cell lines for use in facilitating the development of high capacity adenoviral vectors
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins

Also Published As

Publication number Publication date
CA2213343C (en) 2009-09-01
AU698254B2 (en) 1998-10-29
AU4980496A (en) 1996-09-11
EP0811069B1 (de) 2008-05-28
US5770442A (en) 1998-06-23
EP0811069A1 (de) 1997-12-10
US20030166286A1 (en) 2003-09-04
US6576456B2 (en) 2003-06-10
US20020099024A1 (en) 2002-07-25
WO1996026281A1 (en) 1996-08-29
DE69637545D1 (de) 2008-07-10
JPH11500315A (ja) 1999-01-12
CA2213343A1 (en) 1996-08-29

Similar Documents

Publication Publication Date Title
ATE397075T1 (de) Chimärisches , adenovirales faserprotein und verfahren zu dessen verwendung
NZ323834A (en) Chimeric adenovirus coat protein vectors and methods for gene transfer to cells
ATE382695T1 (de) Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven
FI951138A (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
ATE332363T1 (de) Rekombinanter adenovirus welcher eine chimäre penton-base aufweist
FI943389A (fi) Bacillus-lajista saatu ksylanaasi, tällaisen ksylanaasin ja muiden proteiinien ekspressiovektori, niiden isäntäorganismit ja käyttö
NZ336829A (en) Adenoviruses having altered hexon proteins which present epitopes that are not recognised by neutralizing antibodies to the unmodified adenovirus of another serotype
CA2321177A1 (en) Recombinant fibronectin-based extracellular matrix for wound healing
TR199900666T2 (xx) �nsan paratormonu ile ilgili peptidlere kar�� antikor.
DE69522385D1 (de) Computersystem zur Ausführung von Verzweigungsbefehlen
DE69632827D1 (de) Materialen und methoden im zusammenhang mit bindung und präsentation von substanzen auf zelloberflächen
ATA907698A (de) Pipelineverteilungsnetzwerksysteme für den transport von flüssigerdgas
DK549188D0 (da) Lymfocythaemmende hla-peptider
EP0871661A4 (de) Neue proteindomäne, welche tyrosin-pharphoryliarte proteine bindet
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
FI970097A (fi) Proteiinit, jotka ovat peräisin nisäkkäiden maksasta ja niiden käyttö onkologiassa
FI971275A (fi) Inaktivoidun IVa2-geenin käsittävät epätäydelliset yhdistelmä-DNA-tekniset adenovirukset
AU7423391A (en) Dna constructs for the expression of proteins in the mammary gland of transgenetic mammals
ATE285474T1 (de) Haemophilus adhäsionsproteinen
PT625157E (pt) Epitopes p1a1 e p1a2 da gpiiia da plaqueta sua preparacao e utilizacao
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
SE8502540L (sv) Stabilt tandvardsmedel innehallande dextranas
NZ512596A (en) Cell line expressing non-native cell surface receptors
SE9502595D0 (sv) Novel DNA and peptide sequence and related expression vector
BR1101121A (pt) Vetor adenovirótico recombinante e processos de uso

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties